HalioDx is an immuno-oncology diagnostic company providing oncologists and biopharmaceutical companies with first-in-class Immune-based diagnostic products and services to guide cancer care and contribute to precision medicine in the era of immuno-oncology and combination therapies.
HalioDx provides immune scoring solutions including Immunoscore®, an in vitro diagnostic test allowing to predict patient outcome. The test is commercially available for localized colon cancer in more than 20 countries.
HalioDx has also developed unique offer based on its expertise in immuno-oncology, with a complete suite of biomarker profiling services, a world-class data analysis and biostatistics platform, CLIA-certified laboratories in Europe and in the US to develop, manufacture, register and market IVD products. HalioDx the preferred partner of a growing numbers of Biopharma developing therapeutic antibodies, vaccines, chemotherapies, oncolytic peptides, and CAR-T cell therapies for immuno-oncology interventions.
Contact: Vincent FERT, Co-Founder, President & CEO – tel: 33 491 29 30 90